Cancer Treatment and Research:
HB 1347 would substantially revise Florida’s cancer research and treatment framework by expanding the existing Casey DeSantis Cancer Research Program and creating new structures within the Department of Health to support cancer research, treatment innovation, and data collection. The bill authorizes the department to establish the Florida Cancer Research Network, make grant funding available to eligible Florida-based providers and entities, and direct funds to NCI-designated cancer centers and centers working toward designation. It also creates the Cancer Connect Collaborative to oversee the network, advise on policy and grantmaking, and develop a long-range plan for the state’s cancer research efforts.
The bill also expands reporting and accountability requirements. Licensed providers that diagnose, treat, or screen for cancer would have to submit patient-reported outcomes and quality-of-care data to the Florida Cancer Data System, including screening rates, timeliness of diagnosis and treatment, survival and complication rates, palliative and hospice care measures, and long-term survivorship outcomes. The Department of Health would also create an online repository of best practices on the Florida Cancer Connect website covering screening, diagnosis, treatment, clinical trials, prevention, and survivorship. In addition, the bill creates a Cancer Connect Collaborative Research Incubator to fund a targeted area of cancer research for a five-year period beginning in 2026, with required reports and evaluations through 2031.
HB 1347 would amend s. 381.915, Florida Statutes, to broaden the state’s cancer research program, create new advisory and grantmaking bodies, and impose new data-reporting and oversight obligations on cancer providers and grant recipients. It would affect the Department of Health, participating cancer centers, hospitals, clinics, researchers, and training programs by tying state funding to eligibility criteria, quarterly reporting, audits, and outcome-based performance measures. The bill also adds confidentiality protections for proprietary business information and creates a new open-government exemption for certain collaborative meetings and records, subject to sunset review.
The bill appears to have been generally supportive of cancer research, treatment innovation, and expanded access to care, especially in rural and underserved areas. Its structure emphasizes state investment, coordination, and accountability, suggesting a policy goal of making Florida a leader in cancer care and research. However, the bill ultimately died in the Health Professions & Programs Subcommittee, indicating that despite the policy support reflected in the text, it did not advance through the House process. The context notes that a companion bill passed in the Senate, which suggests the concept had some legislative traction even though this House bill did not move forward.
The most likely areas of contention are the bill’s funding structure, its preferential allocation framework for NCI-designated and near-designated cancer centers, and the extensive new reporting and oversight requirements imposed on providers. The bill also requires a cancer center to endorse an annual report or produce an equivalent independent report to remain eligible for funding, which could be viewed as a strong compliance condition. Another potential point of debate is the creation of confidentiality and meeting-exemption provisions for proprietary business information, which may raise transparency concerns. Finally, the bill’s targeted research incubator and long-term funding commitments may have prompted questions about prioritization, administrative burden, and the distribution of state resources among institutions.